DRG Epidemiology's coverage of multiple sclerosis (MS) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed prevalence and the diagnosed incidence of MS for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan, and 10 years for the other countries covered in this report.

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

DRG Epidemiology's MS forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of MS and the number of new diagnoses of MS?
  • In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of MS and the number of new diagnoses of MS?
  • How will improvements in survival change the number of people living with a diagnosis of MS?
  • Of all people diagnosed with MS, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of MS over the forecast period?

In addition to the total number of cases for each forecast year, DRG Epidemiology also provides at least ten years of forecast data for the following MS subpopulations:

  • Diagnosed incident cases by disease subtype.
  • Diagnosed prevalent cases by disease subtype.
  • Diagnosed prevalent cases of CP-MS by disease subtype.
  • Diagnosed prevalent cases of RR-MS and CIS by disease subtype.
  • Diagnosed prevalent cases of CIS by treatment status.
  • Diagnosed prevalent cases of RR-MS by treatment status.
  • Diagnosed prevalent cases of PP-MS by treatment status.
  • Diagnosed prevalent cases of SP-MS by treatment status.

Note: Coverage may vary by country.

Table of contents

  • Multiple Sclerosis - Epidemiology - Emerging Markets

Author(s): Sunali D. Goonesekera, SM

Sunali Goonesekera is an Associate Epidemiologist at Decision Resources Group.

Sunali holds a Master’s degree in Epidemiology from the Harvard School of Public Health and a B.A. in Biology (Honors) from Dartmouth College. Prior to joining Decision Resources Group, Sunali conducted epidemiological research and lead authored two manuscripts on racial/ethnic disparities in metabolic diseases at the New England Research Institutes. She has contributed to multiple publications in peer-reviewed journals in epidemiology and in the biological sciences.


Related Reports

Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis (US)

Three disease-modifying therapies (DMTs)—EMD Serono’s Mavenclad, Novartis’s Mayzent, and Biogen’s Vumerity—joined the crowded U.S. multiple sclerosis (MS) market just...

View Details

Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis Multiple Sclerosis 2020 – Main Report Dashboard (US)

With more than a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and more in the pipeline, the treatment journey for U.S. MS patients continues...

View Details

Multiple Sclerosis - Unmet Need - Detailed, Expanded Analysis - Relapsing Forms Of MS (US/EU)

A growing number of clinically unique disease-modifying therapies (DMTs) have been approved for the treatment of relapsing forms of multiple sclerosis...

View Details

Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)

With more than a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and more in the pipeline, the treatment journey for U.S. MS patients continues...

View Details